Clinical outcome with different doses of low-molecular-weight heparin in patients hospitalized for COVID-19

A pro-thrombotic milieu and a higher risk of thrombotic events were observed in patients with CoronaVirus disease-19 (COVID-19). Accordingly, recent data suggested a beneficial role of low molecular weight heparin (LMWH), but the optimal dosage of this treatment is unknown. We evaluated the associat...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Thromb Thrombolysis
Autors principals: Mennuni, Marco G., Renda, Giulia, Grisafi, Leonardo, Rognoni, Andrea, Colombo, Crizia, Lio, Veronica, Foglietta, Melissa, Petrilli, Ivan, Pirisi, Mario, Spinoni, Enrico, Azzolina, Danila, Hayden, Eyal, Aimaretti, Gianluca, Avanzi, Gian Carlo, Bellan, Mattia, Cantaluppi, Vincenzo, Capponi, Andrea, Castello, Luigi M., D’Ardes, Damiano, Corte, Francesco Della, Gallina, Sabina, Krengli, Marco, Malerba, Mario, Pierdomenico, Sante D., Savoia, Paola, Zeppegno, Patrizia, Sainaghi, Pier P., Cipollone, Francesco, Patti, Giuseppe
Format: Artigo
Idioma:Inglês
Publicat: Springer US 2021
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7919624/
https://ncbi.nlm.nih.gov/pubmed/33649979
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11239-021-02401-x
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars